-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70

Benzinga·09/22/2026 12:23:40
Listen to the news
JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $76 to $70.